TABLE OF CONTENTS
1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET 39
1.4 CURRENCY AND PRICING 41
1.5 LIMITATIONS 41
1.6 MARKETS COVERED 41
2 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET: SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 MULTIVARIATE MODELLING 51
2.7 PRODUCT LIFELINE CURVE 51
2.8 DBMR MARKET POSITION GRID 52
2.9 VENDOR SHARE ANALYSIS 54
2.10 MARKET END USER COVERAGE GRID 55
2.11 SECONDARY SOURCES 56
3 EXECUTIVE SUMMARY 57
4 PREMIUM INSIGHTS 59
4.1 PORTERS FIVE FORCES 60
4.2 PESTEL ANALYSIS 61
4.3 STRATEGIC INITIATIVES 62
5 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, REGULATION 63
6 MARKET OVERVIEW 65
6.1 DRIVERS 67
6.1.1 INCREASING INCIDENCES OF CHRONIC AND COMMUNICABLE EYE DISEASES 67
6.1.2 INCREASED CONSUMER AWARENESS FOR LASER TREATMENTS 67
6.1.3 INCREASING ADOPTION OF OUTPATIENT PROCEDURES 68
6.1.4 RISING DEMAND FOR MINIMALLY INVASIVE SURGICAL PROCEDURES 69
6.2 RESTRAINTS 70
6.2.1 HIGH COST OF OPHTHALMOLOGY LASER PROCEDURES 70
6.2.2 STRINGENT REGULATORY POLICIES 70
6.3 OPPORTUNITIES 71
6.3.1 TECHNOLOGICAL ADVANCEMENTS IN OPHTHALMOLOGY 71
6.3.2 EMERGING MARKETS AND GOVERNMENT FUNDING 72
6.4 CHALLENGES 73
6.4.1 LACK OF SKILLED PROFESSIONALS 73
6.4.2 SAFETY CONCERNS 73
7 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, BY PRODUCT 75
7.1 OVERVIEW 76
7.2 EXCIMER LASERS 79
7.2.1 ARF 80
7.2.2 KRF 80
7.2.3 XECL 80
7.2.4 XEFL 80
7.2.5 F2 80
7.2.6 XEBR 80
7.3 FEMTOSECOND LASERS 80
7.3.1 SEMICONDUCTOR LASERS 81
7.3.2 SOLID-STATE BULK LASERS 82
7.3.3 FREQUENCY-CONVERTED SOURCES 82
7.3.4 FIBER LASERS 82
7.3.5 DYE LASERS 82
7.3.6 OTHERS 82
7.4 ND:YAG LASERS 82
7.4.1 ND: YAG LASER AT 1064 NM 83
7.4.2 ND: YAG GREEN LASER AT 532 NM 83
7.5 DIODE LASERS 83
7.6 OTHERS 84
8 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, BY TYPE 85
8.1 OVERVIEW 86
8.2 PHOTOCOAGULATION LASERS 89
8.3 SELECTIVE LASER TRABECULOPLASTY (SLT) 89
8.4 PHOTODISRUPTION LASERS 90
9 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, BY APPLICATION 92
9.1 OVERVIEW 93
9.2 THERAPEUTICS 96
9.2.1 CATARACT REMOVAL 97
9.2.2 GLAUCOMA TREATMENT 97
9.2.3 DIABETIC RETINOPATHY TREATMENT 97
9.2.4 REFRACTIVE ERROR CORRECTION 97
9.2.5 AMD TREATMENT 97
9.2.6 OTHERS 97
9.3 DIAGNOSTICS 98
9.3.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 99
9.3.2 SCANNING LASER OPHTHALMOSCOPE (SLO) 99
10 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, BY GASES 100
10.1 OVERVIEW 101
10.2 NOBLE GAS 104
10.2.1 ARGON 105
10.2.2 XENON 105
10.2.3 KRYPTON 105
10.3 HALOGEN GAS 105
10.3.1 CHLORINE 106
10.3.2 BROMINE 106
10.3.3 FLOURINE 106
10.4 BUFFER GAS 106
10.4.1 HELIUM 107
10.4.2 NEON 107
10.5 OTHERS 108
11 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, BY END USER 109
11.1 OVERVIEW 110
11.2 HOSPITALS 113
11.3 CLINICS 113
11.4 OTHERS 114
12 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, BY REGION 116
12.1 MIDDLE EAST AND AFRICA 117
12.1.1 SOUTH AFRICA 126
12.1.2 SAUDI ARABIA 130
12.1.3 U.A.E. 134
12.1.4 EGYPT 138
12.1.5 ISRAEL 142
12.1.6 REST OF MIDDLE EAST AND AFRICA 146
13 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET: COMPANY LANDSCAPE 147
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 147
14 SWOT ANALYSIS 148
15 MIDDLE EAST & AFRICA OPHTHALMOLOGY LASERS MARKET, CPS 149
15.1 BAUSCH & LOMB INCORPORATED 149
15.1.1 COMPANY SNAPSHOT 149
15.1.2 REVENUE ANALYSIS 149
15.1.3 COMPANY SHARE ANALYSIS 150
15.1.4 PRODUCT PORTFOLIO 150
15.1.5 RECENT DEVELOPMENT 150
15.2 JOHNSON & JOHNSON, INC. 151
15.2.1 COMPANY SNAPSHOT 151
15.2.2 REVENUE ANALYSIS 151
15.2.3 COMPANY SHARE ANALYSIS 152
15.2.4 PRODUCT PORTFOLIO 152
15.2.5 RECENT DEVELOPMENT 152
15.3 ZEISS 153
15.3.1 COMPANY SNAPSHOT 153
15.3.2 REVENUE ANALYSIS 153
15.3.3 COMPANY SHARE ANALYSIS 154
15.3.4 PRODUCT PORTFOLIO 154
15.3.5 RECENT DEVELOPMENT 154
15.4 ALCON 155
15.4.1 COMPANY SNAPSHOT 155
15.4.2 REVENUE ANALYSIS 155
15.4.3 COMPANY SHARE ANALYSIS 156
15.4.4 PRODUCT PORTFOLIO 156
15.4.5 RECENT DEVELOPMENT 156
15.5 NIDEK CO., LTD 157
15.5.1 COMPANY SNAPSHOT 157
15.5.2 REVENUE ANALYSIS 157
15.5.3 COMPANY SHARE ANALYSIS 158
15.5.4 PRODUCT PORTFOLIO 158
15.5.5 RECENT DEVELOPMENT 158
15.6 ARC LASER GMBH 159
15.6.1 COMPANY SNAPSHOT 159
15.6.2 PRODUCT PORTFOLIO 159
15.6.3 RECENT DEVELOPMENT 159
15.7 AUROLAB 160
15.7.1 COMPANY SNAPSHOT 160
15.7.2 PRODUCT PORTFOLIO 160
15.7.3 RECENT DEVELOPMENT 160
15.8 CALMAR LASER 161
15.8.1 COMPANY SNAPSHOT 161
15.8.2 PRODUCT PORTFOLIO 161
15.8.3 RECENT DEVELOPMENT 161
15.9 IRIDEX CORPORATION 162
15.9.1 COMPANY SNAPSHOT 162
15.9.2 REVENUE ANALYSIS 162
15.9.3 PRODUCT PORTFOLIO 163
15.9.4 RECENT DEVELOPMENT 163
15.10 IVIS TECHNOLOGIES 164
15.10.1 COMPANY SNAPSHOT 164
15.10.2 PRODUCT PORTFOLIO 164
15.10.3 RECENT DEVELOPMENT 164
15.11 LENSAR, INC. 165
15.11.1 COMPANY SNAPSHOT 165
15.11.2 REVENUE ANALYSIS 165
15.11.3 PRODUCT PORTFOLIO 166
15.11.4 RECENT DEVELOPMENT 166
15.12 LUMENIS BE LTD. 167
15.12.1 COMPANY SNAPSHOT 167
15.12.2 PRODUCT PORTFOLIO 167
15.12.3 RECENT DEVELOPMENT 167
15.13 LIGHTMED 168
15.13.1 COMPANY SNAPSHOT 168
15.13.2 PRODUCT PORTFOLIO 168
15.13.3 RECENT DEVELOPMENT 168
15.14 MEDA CO., LTD. 169
15.14.1 COMPANY SNAPSHOT 169
15.14.2 PRODUCT PORTFOLIO 169
15.14.3 RECENT DEVELOPMENT 169
15.15 OD-OS 170
15.15.1 COMPANY SNAPSHOT 170
15.15.2 PRODUCT PORTFOLIO 170
15.15.3 RECENT DEVELOPMENT 170
15.16 QUANTEL MEDICAL (A SUBSIDIARY OF LUMIBIRD MEDICAL) 171
15.16.1 COMPANY SNAPSHOT 171
15.16.2 REVENUE ANALYSIS 171
15.16.3 PRODUCT PORTFOLIO 172
15.16.4 RECENT DEVELOPMENT 172
15.17 SCHWIND EYE-TECH-SOLUTIONS 173
15.17.1 COMPANY SNAPSHOT 173
15.17.2 PRODUCT PORTFOLIO 173
15.17.3 RECENT DEVELOPMENT 173
15.18 TOPCON 174
15.18.1 COMPANY SNAPSHOT 174
15.18.2 REVENUE ANALYSIS 174
15.18.3 PRODUCT PORTFOLIO 175
15.18.4 RECENT DEVELOPMENT 175
15.19 ZIEMER OPHTHALMIC SYSTEMS AG 176
15.19.1 COMPANY SNAPSHOT 176
15.19.2 PRODUCT PORTFOLIO 176
15.19.3 RECENT DEVELOPMENT 176
16 QUESTIONNAIRE 177
17 RELATED REPORTS 180

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.